Monday, September 12, 2022
Registration |
2.00 pm-5.30 pm
|
|
|
Welcome addresses & Opening Keynote lecture |
5.45 pm-7.00 pm
|
Chair: Roland Brosch, Institut Pasteur, France |
0
5.45 pm |
Welcome addresses, the Director of the Institut Pasteur Stewart COLE and members of the organizing committee
Stewart Cole Institut Pasteur, Paris, France
|
1
6.15 pm |
Developing a controlled human infection model for TB
Helen McShane University of Oxford, Oxford, United Kingdom
|
|
Welcome Reception (buffet dinner) at CIS Institut Pasteur |
7.00 pm-9.00 pm
|
|
|
Tuesday, September 13, 2022
Session1: From Mycobacterial genomics to global epidemiology & resistance prediction |
08.30 am-10.15 am
|
Chairs: Howard Takiff, Institut Pasteur, France - Philip Supply, CIIL - Center for Infection and Immunity of Lille, France |
2
08.30 am |
Transmission and evolution of MDR Mycobacterium tuberculosis complex strains
Stefan Niemann Molecular and Experimental Mycobacteriology, Research Center Borstel, Germany German Center for Infection Research, Borstel Site, Germany
|
3
08.55 am |
Cis-regulatory effects of constitutive and context-specific intercellular mosaic methylation in M. tuberculosis
Samuel Modlin San Diego State University, San Diego, United States
|
4
09.10 am |
Mycobacterial diversity’s lens on public health
Bouke De Jong Institute of Tropical Medicine, Antwerp, Belgium
|
5
09.35 am |
Epistasis defines the transmission fitness of multidrug-resistant Mycobacterium tuberculosis
Etthel Windels Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland Swiss Institute of Bioinformatics, Lausanne, Switzerland
|
6
09.50 am |
Fast RNA-based drug susceptibility testing fills the gap between slow phenotypic and ultra-fast DNA-based resistance detection
Margo Maex Scientific Service Bacterial Diseases - Infectious Diseases in Humans, Siensano, Brussels, Belgium
|
|
Coffee break |
10.15 am-10.45 am
|
|
|
Session 2: Mycobacterial Biology & Physiology I |
10.45 am-12.30 pm
|
Chairs: Sabine Ehrt, Weill Cornell Medical College, United States - Jeremy Rock, Rockefeller University, United States |
7
10.45 am |
Finding the most "essential" essential genes in M. tuberculosis
Jeremy Rock Rockefeller University, New York, United States
|
8
11.10 am |
ADP-ribosylation of DNA in Mycobacterium tuberculosis – from “How” to “Why?”
Graham Stewart Dept of Microbial Sciences, University of Surrey, Guildford, United Kingdom
|
9
11.25 am |
TbD1 deletion in Mycobacterium tuberculosis adaptation to the human host
Daria Bottai University of Pisa, Pisa, Italy
|
10
11.50 am |
Phase variation as a major mechanism of adaptation in Mycobacterium tuberculosis complex
Maha Farhat Biomedical Informatics, Harvard Medical School, Boston, United States
|
11
12.05 pm |
Mycobacterial determinants of intrinsic multidrug tolerance and resistance
Sabine Ehrt Cornell Medical College, New York, United States
|
|
Poster session 1 |
1.45 pm-3.30 pm
|
|
|
Session 3: Mycobacterial Biology & Physiology II |
3.30 pm-4.55 pm
|
Chairs: Giulia Manina, Institut Pasteur, France - Sarah Fortune, Harvard University, United States |
12
3.30 pm |
It’s about time: Antibiotic resilience as a driver of treatment failure in tuberculosis
Sarah Fortune Harvard University, Boston, United States
|
13
3.55 pm |
Exploring horizontal gene transfer in predominantly clonal tuberculosis-causing mycobacteria
Jan Madacki Unit for Integrated Mycobacterial Pathogenomics, Institut Pasteur, Paris, France
|
14
4.10 pm |
The Mycobacterium tuberculosis protein O-phosphorylation landscape
Christoph Grundner Seattle Children's Research Institute, Seattle, United States University of Washington, Seattle, United States
|
15
4.25 pm |
Pheno-tuning: A strategy to undermine mycobacterial cells
Giulia Manina Laboratory of Microbial Individuality and Infection, Institut Pasteur, Paris, France
|
|
Coffee break |
4.50 pm-5.20 pm
|
|
|
Session 4: Drug development & resistance/persistence management |
5.20 pm-6.50 pm
|
Chairs: Bree Aldridge, Tufts University, United States - Santiago Ramón García, ARAID Foundation, Spain |
16
5.20 pm |
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations
Santiago Ramón García ARAID Foundation, Zaragoza, Spain
|
17
5.45 pm |
Targeted protein self-degradation as a novel therapeutic strategy for tuberculosis
Harim Won Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
|
18
6.00 pm |
Sanfetrinem Cilexetil - From (re-) discovery to clinical trial
Robert Bates GSK Medicines Development Centre, Tres Cantos, Spain
|
19
6.25 pm |
Design Principles of Combination Therapies for TB
Bree Aldridge Tufts University, Boston, United States
|
|
Wine cheese reception at CIS Institut Pasteur |
7.00 pm-9.00 pm
|
|
|
Wednesday, September 14, 2022
Session 5: Biomarkers and host responses |
08.30 am-10.15 am
|
Chairs: Lalita Ramakrishnan, University of Cambridge, United Kingdom - Simone Joosten, Leiden University, The Netherlands |
20
08.30 am |
Mycobacterial growth control in natural vs vaccine induced protection
Simone Joosten Department of Infectious Diseases, Leiden University, Leiden, The Netherlands
|
21
08.55 am |
A Mycobacterium tuberculosis fingerprint in human breath allows tuberculosis diagnosis
Jérôme Nigou Institut de Pharmacologie et de Biologie Structurale, CNRS - University of Toulouse, France
|
22
09.10 am |
Mycobacterial virulence and macrophage mitochondrial metabolism face off
Lalita Ramakrishnan University of Cambridge, Cambridge, United Kingdom
|
23
09.35 am |
Human Antibodies Targeting a Transporter Mediate Protection Against Tuberculosis
Natalia Freund Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
|
24
09.50 am |
Roles of antibody characteristics in the protection against TB - from epitope to Fc and isotype significance
Jacqueline Achkar Albert Einstein College, New York, United States
|
|
Coffee break |
10.25 am-10.55 am
|
|
|
Session 6: Live attenuated vaccines & mechanisms of attenuation |
10.55 am-12.25 pm
|
Chairs: Carlos Martin, University of Zargossa, Spain - Andreas Kupz, James Cook University, Australia |
25
10.55 am |
BCG::ESAT6-PE25SS – a new recombinant BCG strain – insights into delivery and protective mechanisms
Andreas Kupz James Cook University, Cairns, Australia
|
26
11.20 am |
MTBVAC from the lab to clinical efficacy trials, the moment of truth 100 years after BCG
Carlos Martin University of Zargossa, Zaragossa, Spain
|
27
11.45 am |
Mind the Gap: Functional Characterisation of the Mycobacterial Virulence Protein Erp
Jonathan Shanahan Department of Medicine, Molecular Immunity Unit, University of Cambridge, United Kingdom
|
28
12.00 pm |
ESX-1-proficient BCG vaccines: challenges and opportunities
Roland Brosch Institut Pasteur, Paris, France
|
|
Poster session 2 |
1.45 pm-3.15 pm
|
|
|
Session 7: Mycobacterial Host-Pathogen interactions |
3.15 pm-5.00 pm
|
Chairs: Maximiliano G. Gutierrez, The Francis Crick Institute, United Kingdom - Olivier Neyrolles, Institut for Pharmacology and Structural Biology, France |
29
3.15 pm |
Mycobacterial resistance to metal stress during infection
Olivier Neyrolles Institut for Pharmacology and Structural Biology, Toulouse, France
|
30
3.40 pm |
Pre-existing heterogeneity of inducible nitric oxide synthase expression drives differential growth of Mycobacterium tuberculosis in macrophages
Ophélie Rutschmann UPKIN, EPFL, Lausanne, Switzerland
|
31
3.55 pm |
Is Mycobacterium tuberculosis the greatest cell biologist in the world?
Maximiliano G. Gutierrez The Francis Crick Institute, London, United Kingdom
|
32
4.20 pm |
Making mistakes in the goldilocks zone: mistranslation as a novel form of mycobacterial virulence
Babak Javid UCSF, San Francisco, United States Tsinghua University, Beijing, China
|
33
4.35 pm |
Drivers of diversity in tuberculosis in vivo
David Russell Cornell University, Ithaca, United States
|
|
Coffee break |
5.00 pm-5.30 pm
|
|
|
Session 8: Non-rodent animal models for TB |
5.30 pm-7.00 pm
|
Chairs: Laura Via, NIH NIAID, United States - Stephen Gordon, University College Dublin, Ireland |
34
5.30 pm |
One Health analysis of Mycobacterium bovis
Stephen Gordon University College Dublin, Dublin, Ireland
|
35
5.55 pm |
Drosophila melanogaster as a host model to study mycobacterial host-pathogen interactions
Marte Singsås Dragset Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology, Trondheim, Norway Germans Trias i Pujol Research Institute, Badalona, Spain
|
36
6.10 pm |
Implementation of a cynomolgus macaque model of tuberculosis
Candie Joly IMVA-HB/IDMIT, CEA, Fontenay Aux Roses, France
|
37
6.35 pm |
Efficacy of TB regimens in an NHP model: focusing on pathology
Laura Via Tuberculosis Research Section, NIH NIAID, Bethesda, United States
|
|
On your own for dinner |
7.00 pm-11.00 pm
|
|
|
Thursday, September 15, 2022
Session 9: Emerging mycobacterial pathogens |
08.30 am-10.15 am
|
Chairs: Marcel Behr, McGill University, Canada - Jean-Louis Herrmann, Université Paris-Saclay, France |
38
08.30 am |
Mycobacterium abscessus fitness modulation in vivo: a bacterial trait or ... a bacterial trait
Jean-Louis Herrmann Université Paris-Saclay, Saint-Quentin-en-Yvelines, France
|
39
08.55 am |
The small RNA B11 is a master regulator of ESX-4 secretion and M. abscessus pathogenesis
Daniel Barkan Hebrew University, Rehovot, Israel
|
40
09.10 am |
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens
Giulia Degiacomi Department of Biology and Biotechnologies, University of Pavia, Italy
|
41
09.25 am |
Unpacking the molecular determinants of Mycobacterium abscessus infections
Virginia Pichler Microbiology & Immunology, University of British Columbia, Vancouver, Canada CNRS. UMR 9004, Université de Montpellier, Institut de Recherche en Infectiologie de Montpellier (IRIM), France
|
42
09.40 am |
M. orygis: zTB’s missing link
Marcel Behr McGill University, Montreal, Canada
|
|
Coffee break |
10.05 am-10.35 am
|
|
|
Session 10: Host-responses and host-directed therapies |
10.35 am-12.35 pm
|
Chairs: Priscille Brodin, INSERM, Institut Pasteur de Lille, France - Jan Rybniker, University of Cologne, Germany |
43
10.35 am |
Exploiting MAP-kinase signaling as a host directed target in tuberculosis
Jan Rybniker University of Cologne, Cologne, Germany
|
44
11.00 am |
WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis
Julius Brandenburg Research Center Borstel, Germany
|
45
11.15 am |
Targeting human macrophages to improve the efficacy of anti-TB drugs
Ludovic Tailleux Institut Pasteur, Paris, France
|
46
11.40 am |
Host regulators of phagosomal membrane integrity in TB infection
Charul Jani Dr. Amy Barczak, Ragon Institute of MGH, MIT and Harvard, Cambridge, United States
|
47
11.55 am |
Neutrophil-driven immunosuppressive feedback loops underlying susceptibility to M. tuberculosis
Dmitri Kotov Divison of Immunology and Pathogenesis, University of California, Berkeley, United States Howard Hughes Medical Institute, University of California, Berkeley, United States
|
48
12.10 pm |
Is intracellular activity a potent driver for novel TB drug development?
Priscille Brodin INSERM, Institut Pasteur de Lille, France
|
|
Poster session 3 |
1.45 pm-3.15 pm
|
|
|
Session 11: Biochemistry & chemical biology / drugs I |
3.15 pm-4.35 pm
|
Chairs: Hedia Marrakchi, IPBS, France - Clifton Barry, NIH NIAID, United States |
49
3.15 pm |
Exploiting a Bacterial Enzyme for Selective Prodrug Activation: Mycobacterium tuberculosis N-acetylates 5-aminomethyl oxazolidinones
Clifton Barry Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, United States
|
50
3.40 pm |
Expression of a novel mycobacterial phosphodiesterase successfully lowers cAMP levels resulting in reduced tolerance to cell-wall targeting antimicrobials
Gerald Larrouy-Maumus MRC-CMBI Imperial College London, United Kingdom
|
51
3.55 pm |
Targeting mycolic condensation enzymes: from screens to insights
Hedia Marrakchi IPBS, Toulouse, France
|
52
4.20 pm |
Solution structure of the type I polyketide synthase Pks13 from Mycobacterium tuberculosis
Cécile Bon IPBS, CNRS/Université de Toulouse, France
|
|
Coffee break |
4.35 pm-5.00 pm
|
|
|
Session 12: Biochemistry & chemical biology / drugs II |
5.00 pm-6.05 pm
|
Chairs: Thomas Marlovits, Institute of Structural and Systems Biology, Germany - Pedro Alzari, Structural Microbiology, Institut Pasteur, France |
53
5.00 pm |
Novel insights into mycobacterial cell division mechanisms using C. glutamicum as a model organism
Annemarie Wehenkel Institut Pasteur, Paris, France
|
54
5.25 pm |
Compartment-specific proximity labeling uncovers the exposure of Type VII ESX secretion system substrates to the mycobacterial periplasm
Jessica Seeliger Department of Pharmacological Sciences, Stony Brook University, United States
|
55
5.40 pm |
Structure and dynamics of a mycobacterial type VII secretion system
Thomas Marlovits Institute of Structural and Systems Biology, Hamburg, Germany
|
|
Congress dinner (Musée des Arts Forains) (with reservation) |
8.00 pm-11.00 pm
|
|
|
Friday, September 16, 2022
Session 13: Human susceptibility & Clinical trials |
09.00 am-10.30 am
|
Chairs: Anne O'Garra, The Francis Crick Institute, United Kingdom - Gerhard Walzl, Stellenbosch University, South Africa |
56
09.00 am |
Human Genetics of tuberculosis : the TYK2 story
Laurent Abel Inserm, Necker, Paris, France
|
57
09.25 am |
Systems immunomonitoring to support development of new treatments and vaccines for TB
Darragh Duffy Institut Pasteur, Paris, France
|
58
09.40 am |
Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis
Anne O'Garra The Francis Crick Institute, London, United Kingdom
|
59
10.05 am |
Using Biomarkers to Predict TB Treatment Duration
Gerhard Walzl Stellenbosch University, Stellenbosch, South Africa
|
|
Coffee break |
10.30 am-11.00 am
|
|
|
Session 14: Closing Keynote lecture and outlook |
11.00 am-12.00 pm
|
Chairs: Roland Brosch, Institut Pasteur, France - Pedro Alzari, Structural Microbiology, Institut Pasteur, France |
60
11.00 am |
Drugs hug, bugs chug - genetic-chemical synergy in mycobacteria
Eric Rubin Harvard University, Boston, United States
|
0
11.50 am |
Closing comments / End of congress
|
|
Persistance-webSoft
congresoft.frplateforme dédiée aux manifestations
Tel. : 01 84 17 20 55 / 06 89 19 34 06
E-mail : contact@congresoft.fr
La première plateforme Française de gestion de manifestations regroupant la billeterie, la gestion des hébergements, une boutique en ligne, la gestion des surfaces d'exposition et la gestion complète du programme scientifique.
Organisation de Congrès, manifestations, Séminiaires, Colloques